Nottingham University Hospital NHS Trust in the U.K. has announced a new state of the art facility utilizing technology from enterprise partners, including Cisco. The new £6.6 million East Midlands Cystic Fibrosis Adult CF Centre campus at Nottingham University Hospital’s (NUH) NHS Trust City Hospital is designed to…
Bayer HealthCare, a global leader in respiratory medicine, recently announced it has received qualified infectious disease product (QIDP) designation from the US Food and Drug Administration for two pipeline inhalation antibiotic drugs: Amikacin inhale and Ciprofloxacin dry powder. The approval of novel inhaled antibiotics are of particular interest to the…
In the United Kingdom, The Cystic Fibrosis Trust along with the children’s charity Action Medical Research, are funding a laboratory test of an inhaled treatment targeting lung dehydration in Cystic Fibrosis. Cystic fibrosis (CF) is a condition that usually affects children and young people and includes symptoms such…
Last month, the Cystic Fibrosis Foundation celebrated the 20th year of its annual golf tournament and successful fundraiser, the Ultimate Golf Experience. Over 100 longtime members and supporters of the CFF gathered at the Pinehurst Resort in Durham in North Carolina, where the golfing-fundraising tradition for CF first…
New research on the mechanism of infection of the bacteria Pseudomonas aeruginosa entitled “Surface attachment induces Pseudomonas aeruginosa virulence” by Dr. Albert Siryaporn at Princeton University was recently published in PNAS. The findings are particularly important to the Cystic Fibrosis community, as Pseudomonas aeruginosa is a serious…
Anthera Pharmaceuticals, Inc., a biopharmaceutical company that specializes in research and development of novel treatments for serious and fatal diseases such as lupus, lupus with nephrotic affectation, and exocrine pancreatic insufficiency (EPI) secondary to cystic fibrosis (CF), has just announced that it has partnered with Patheon®, a contract development and commercial…
Cempra, Inc received clearance to initiate Phase 1b and Phase 2 / 3 studies that will test their solithromycin antibiotic in newborn to 17 year-old patients. The experimental antibiotic could eventually offer new therapeutic options to cystic fibrosis patients in fighting bacterial lung infections. Intravenous, oral suspension formulas, and…
Clinical-stage biopharmaceutical company, N30 Pharmaceuticals, recently announced that it raised $30 million in a mezzanine round of financing, which will be used to accelerate the development the company’s investigational therapy for the treatment of cystic fibrosis (CF). The novel drug is called N91115 and N30 Pharma has successfully completed its phase…
The Cystic Fibrosis Foundation (CFF) announced this week that its nonprofit affiliate, Cystic Fibrosis Foundation Therapeutics, has sold its royalty rights for CF treatments developed by Vertex Pharmaceuticals Inc., including the new cystic fibrosis drug Kalydeco. The Foundation sold the rights to Royalty Pharma for…
In a recent study entitled “Modulation of the Maladaptive Stress Response to Manage Diseases of Protein Folding,” a team of researchers showed that in protein misfolding diseases, such as cystic fibrosis and Alzheimer’s disease, the cells’ response to misfolding proteins can actually exacerbate the disease phenotype. The study was published in the …
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.
Get regular updates to your inbox.